Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
ClH/c27-24(25(28
(-)-BAY-K-8644
CHR-2797 exerts antiproliferative effects against a range of tumor cell lines
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
Gefitinib - CAS# 184475-35-2 Size:Solid 2 mg ClH/c27-24(25(28Gefitinib, also known as ZD1839, is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in
US$ 79.99
US$ 36.99
US$ 11.99
US$ 24.99
US$ 126.49